A single dose of recombinant activated factor VII (NovoSeven®) did not impair the function of the coronary artery bypass grafts - Successful treatment of critical bleeding after cardiac surgery in two cases

Transfusion Medicine and Hemotherapy

Volumn 34, Issue 3, 2007, Pages 204-207

  Pfau, Giselher ^a   Schilling, Thomas ^a   Kozian, Alf ^a   Huth, Christof ^a   Schneemilch, Christine E ^a   Heim, Marcell U ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Cardiac surgery; Hemostasis; Recombinant activated factor VII; rFVIIa

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AGED; AORTA GRAFT; ARTICLE; BLEEDING TENDENCY; CARDIOPULMONARY BYPASS; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; GRAFT PATENCY; GRAFT SURVIVAL; HUMAN; MALE; OPEN HEART SURGERY; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; SINGLE DRUG DOSE; SURGICAL PATIENT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34249981725     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101768     Document Type: Article

References (15)

1. Jurk K, Kehrel BE: Inherited and acquired disorders of platelet function. Transfus Med Hemother 2007;34:6-19.
2. Linden MD: The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombolysis 2003;16(3):129-47.
3. Sapsford W: The potential use of recombinant activated factor VII in trauma and surgery. Scand J Surg 2004;93(1):17-23.
4. Aledort LM: rFVIIa - its thrombogenicity. Thromb Haemost 2000;84(3):522-3.
5. Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J: Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 2006;81(3):875-9.
6. McCall P, Story DA, Karapillai D: Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 2006;53(9):926-33.
7. Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH: Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. Ann Thorac Surg 2006;82(5):1779-83.
8. DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha AS: Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 2005;127(5):1828-35.
9. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, et al: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11(suppl 1):S121-7.
10. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J: An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001;93(2):287-9.
11. Stratmann G, Russell IA, Merrick SH: Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg 2003;76(6):2094-7.
12. Kastrup M, von Heymann C, Hotz H, Konertz WF, Ziemer S, Kox WJ, et al: Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 2002;74(3):910-2.
13. Lozano M, Perez-Pujol S: Inherited Macrothrombocytopenias: diagnosis and management. Transfus Med Hemother 2004;31:388-97.
14. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352(8):777-85.
15. Karkouti K, Yau TM, Riazi S, Dattilo KM, Wasowicz M, Meineri M, et al: Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 2006;53(8):802-9.